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LETTERS
Human 
Parvovirus 4 in 
Kidney Transplant 
Patients, France
To the Editor: Human parvovirus 
4 (PARV4) is a recently identiﬁ  ed vi-
rus, distantly related to already known 
members of the family Parvoviridae 
that affect humans and animals. Ini-
tially, PARV4 was characterized in the 
blood of a North American patient who 
had acute viral syndrome; a sequence-
independent ampliﬁ  cation  approach 
was used (1). Molecular analysis of 
the viral prototype genome (5,268 
nt) identiﬁ   ed 2 large, nonoverlap-
ping open reading frames (ORFs) and 
showed limited homology with human 
parvovirus B19 (<30% aa similarity). 
Subsequent phylogenetic analyses 
have shown that at least 2 genotypes 
are identiﬁ  able, differing by ≈8% at 
the nucleotide level (2).
The ﬁ  rst prevalence studies, per-
formed mainly in North America and 
the United Kingdom, reported ﬁ  nd-
ing the virus in plasma samples from 
febrile patients who had symptoms 
resembling those of acute HIV infec-
tion (6%), from cadavers of hepatitis 
C RNA–positive intravenous drug 
users (30%), and in plasma dona-
tions from healthy blood donors (5% 
pooled, 2% individual) (3–5). PARV4 
was also identiﬁ  ed in clotting factor 
VIII concentrate and in plasma pools 
negative for parvovirus B19 DNA 
(5,6). This new virus appears to not 
be restricted solely to blood samples; 
it has been already identiﬁ  ed in bone 
marrow, in various autopsy tissue 
samples from patients with AIDS, and 
in liver tissues of persons with liver 
dysfunctions (7–9). Typical amounts 
of PARV4 DNA identiﬁ  ed in the vari-
ous samples tested ranged from <500 
to >106 copies/mL.
We investigated PARV4 DNA in 
plasma samples collected from cohorts 
of 378 inpatients and 192 healthy blood 
donors from southeastern France dur-
ing 2007: 164 kidney transplant pa-
tients (55 women, 109 men; mean age 
51 ±14 years; mean duration of trans-
plantation 37 ±30 months), 214 hemo-
dialysis patients (88 women, 126 men; 
mean age 65 ±15 years; mean duration 
of dialysis 30 ±28 months), and 192 
voluntary blood donors (86 women, 
106 men; mean age 40 ±21 years).
Blood samples were collected 
in vacuum tubes (Vacutainer SST; 
Becton Dickinson, Meylan, France) 
and then centrifuged. Plasma aliquots 
were stored at –80°C before DNA ex-
traction. Nucleic acids were extracted 
from 1-mL volumes of plasma by us-
ing a nucleic acid extraction machine 
(MagNA Pure LC, Roche Diagnos-
tics, Meylan, France) and eluted 
into 50-μL volumes. Samples were 
screened for PARV4 DNA by real-
time PCR (StepOne Plus, Applied 
Biosystems, Courtaboeuf, France) by 
using a consensus TaqMan PCR sys-
tem composed of conserved primers 
and a ﬂ   uorogenic hydrolysis probe 
located on the ORF2 of the viral ge-
nome (5). Ampliﬁ  cation  reactions 
were performed by using 5 μL of ex-
tracted nucleic acids with the TaqMan 
Fast Universal PCR kit (Applied Bio-
systems) in a ﬁ  nal volume of 20 μL. 
The ampliﬁ   cation conditions were 
95°C for 20 s, followed by 50 cycles 
of 95°C for 1 s and 60°C for 20 s. Us-
ing dilutions of a synthetic template 
corresponding to the target sequence 
(103 nt), we estimated the sensitivity 
of the TaqMan assay to be 10 copies 
of PARV4 DNA.
Positive results were obtained 
from 5 blood samples, all from kidney 
transplant patients (5/164; 3.05%). 
Real-time PCR products were cloned, 
sequenced, and compared with se-
quences of PARV4 already deposited 
in databases. They exhibited 100% 
nucleotide identity in this ORF2 re-
gion with the PARV4 prototype isolate 
(GenBank accession no. AY622943). 
The titer of PARV4 DNA in the posi-
tive samples was low and did not ex-
ceed 500 copies/mL plasma. The 5 
patients (1 woman and 4 men, mean 
age 48 ±18 years, mean duration of 
transplantation 25 ±21 months, no het-
erologous blood transfusions) did not 
show evidence of speciﬁ  c biological 
or clinical dysfunctions.
Whether these 5 patients were in-
fected by kidney graft was impossible 
to determine because kidney trans-
plant tissue samples were unavail-
able for analysis. However, 2 blood 
samples were available for retrospec-
tive analysis for 1 patient (male, 66 
years), who was PARV4 positive 
at 4 months after transplant. These 
samples, collected 1 and 2 months 
before transplant, were negative for 
PARV4 DNA, which suggests pos-
sible transmission of the virus by the 
transplanted organ or reactivation of 
a latent infection resulting from im-
munosuppressive treatments.
PARV4 DNA was not detected 
in any persons in the 2 other cohorts: 
hemodialysis patients and voluntary 
blood donors. Investigations of larg-
er cohorts and/or analyses of plasma 
pools, using optimized molecular ap-
proaches, are required for a better un-
derstanding of the diffusion of PARV4 
in France.
In summary, we found PARV4 in 
the blood of transplant patients and 
determined that for 1 of these patients, 
PAR4 was present only after the trans-
plant procedure. The natural history 
and clinical features of this new parvo-
virus remain largely unknown. Further 
investigations to elucidate the mode of 
transmission and the potential effect 
of PARV4 infection in this category of 
patients are urgently needed.
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Establishment of 
Biomphalaria 
tenagophila Snails 
in Europe
To the Editor: Schistosomiasis, 
known since ancient times, is caused 
by blood ﬂ  ukes (Trematoda: Schisto-
somidae). It is a major communicable 
disease with public health and socio-
economic effects in the developing 
world (1). Among parasitic diseases, 
schistosomiasis ranks second only 
to malaria with regard to the number 
of persons infected and at risk. The 
life cycle of schistosomes is com-
plex, requiring speciﬁ  c  freshwater 
snails as intermediate hosts for lar-
vae development and multiplication. 
Among Schistosoma species that af-
fect humans, Schistosoma mansoni is 
the most likely to invade new areas 
mainly because of the adaptability 
and invasiveness of its intermediate 
host,  Biomphalaria snails. Natural 
populations of these snails are usu-
ally found in tropical standing water 
or freshwater in South America and 
Africa, but they also reach 30° lati-
tude in subtropical areas (1,2). Many 
species of these red-blooded planor-
bid snails (Gastropoda: Basommato-
phora) are able to survive a long time 
when removed from their freshwater 
habitat (1). Of the 34 Biomphalaria 
species, 4 (B. glabrata, B. pfeifferi, B. 
straminea, and B. tenagophila) have 
recently expanded their native ranges 
(3). They have been introduced to ar-
eas where other Biomphalaria species 
are endemic (e.g., Congo and Egypt) 
or to subtropical zones that have no 
frost period (Texas, Louisiana, Flor-
ida, Hong Kong) (3,4). None of the 
known invasions, whether peripheral 
range expansion or long distance dis-
persal, reached the temperate zone. 
Spreading of the blood-ﬂ  uke snails to 
schistosome-free areas may enable the 
parasite to colonize new habitats con-
currently, expanding the potential area 
of clinical schistosomiasis.
We collected these snails in spring 
2005, autumn 2006, and autumn 2007, 
near Răbăgani, Romania, Eastern Eu-
rope (46°45′1.3′′N, 22°12′44.8′′E) in 
a hypothermal spring. Water tempera-
ture was 25°C in the spring and 16°C–
25°C, gradually decreasing, along 
the brook course. In and beside an 
abandoned concrete pool next to the 
spring, we collected 100 shells and 34 
living specimens that macroscopically 
resembled  Biomphalaria spp. snails. 
All 16 dissected animals proved to 
be fully developed adults, according 
to the maturity of their genital organs 
(Figure). Using available identiﬁ  ca-
tion keys (5), we tentatively identiﬁ  ed 
these snails as B. tenagophila. Vouch-
er specimens have been deposited in 
the Hungarian Natural History Muse-
um (accession nos. HNHM96857 and 
HNHM95433).
DNA was extracted from the 
foot muscles of 3 specimens by using 
QIAamp DNA Mini Kit (QIAGEN, 
Hilden, Germany). For ampliﬁ  cation 
of the partial mitochondrial 16S ri-
bosomal RNA gene, we used a PCR 
with primers 16Sar and 16Sbr (6). 
Nucleotide sequences were deter-
mined in both directions. PCR prod-
ucts of ≈430 bp were detected from all 
3 samples. Automatic cycle sequenc-
ing of the randomly selected amplicon 
(GenBank accession no. EU069412) 
showed 99.74% similarity to B. tena-
gophila (AF449615, Brazil).
1812  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 11, November 2008